Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
l-ornithine l-aspartate + silymarin
- Development stage
- Unknown
- Lead developer
- Tigris Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hepatig DS is a combination medication developed by Tigris Lifesciences for the management of various liver disorders within the field of gastroenterology. It typically contains L-ornithine L-aspartate and silymarin. L-ornithine L-aspartate works by reducing blood ammonia levels through the stimulation of the urea cycle and glutamine synthesis, which is particularly beneficial in hepatic encephalopathy. Silymarin, a flavonoid complex extracted from milk thistle, acts as an antioxidant and hepatoprotective agent by stabilizing liver cell membranes and promoting protein synthesis to aid in liver regeneration. The DS designation indicates a Double Strength formulation, providing higher concentrations of the active ingredients compared to the standard version.
- Brand names
- Hepatig DS
- Other names
- L-CorlinaL-Ornithine L-Aspartate + SilymarinLOLA + Silymarin
02
Targets
ASS1 (Argininosuccinate synthase 1)CPS1 (Carbamoyl phosphate synthetase I)GLUL (Glutamine synthetase)OTC (Ornithine carbamoyltransferase)Pol I (RNA polymerase I)RPA1 (Replication protein A1)
Beyond the preview
Go deeper on l-ornithine l-aspartate + silymarin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on l-ornithine l-aspartate + silymarin.